The effects of thiazolidinediones on blood pressure levels – A systematic review

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood Pressure

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/08037050600853720PMID 16864155
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in Rats

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005influential reference
• Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.

  2005cited by this paper
• Effects of Pioglitazone and Metformin on the Development of Hypertension and on Insulin Sensitivity in 1 K 1 C Rats

  2005cited by this paper
• Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.

  2005cited by this paper
• Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.

  2005cited by this paper
• Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.

  2005cited by this paper
• Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes

  2005cited by this paper
• Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats

  2005cited by this paper
• Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.

  2005influential reference
• Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy

  2005cited by this paper
• Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

  2005cited by this paper
• A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.

  2005cited by this paper
• The effect of rosiglitazone on overweight subjects with type 1 diabetes.

  2005cited by this paper
• Risk reduction therapy for syndrome X: comparison of several treatments.

  2005cited by this paper
• Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

  2004cited by this paper
• Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

  2004cited by this paper
• Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.

  2004cited by this paper
• Long-term effects of the PPARγ activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats

  2004cited by this paper
• Rosiglitazone Improves, While Glibenclamide Worsens Blood Pressure Control in Treated Hypertensive Diabetic and Dyslipidemic Subjects via Modulation of Insulin Resistance and Sympathetic Activity

  2004cited by this paper
• Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

  2004cited by this paper
• Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model.

  2004cited by this paper
• Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

  2004cited by this paper
• Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension

  2004cited by this paper
• Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

  2004cited by this paper
• PPAR&ggr; Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice

  2004cited by this paper
• Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

  2004cited by this paper
• Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

  2004cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Ligands Inhibit Rho/Rho Kinase Pathway by Inducing Protein Tyrosine Phosphatase SHP-2

  2004cited by this paper
• Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats.

  2004cited by this paper
• Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.

  2004cited by this paper
• Pioglitazone reduces blood pressure in non-dipping diabetic patients.

  2004influential reference
• Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity

  2004cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.

  2003cited by this paper
• Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

  2003cited by this paper
• Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.

  2003cited by this paper
• Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.

  2003cited by this paper
• Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving Hemodialysis

  2003cited by this paper
• Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

  2003cited by this paper
• Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002)

  2003cited by this paper
• Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.

  2003influential reference
• Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.

  2003cited by this paper
• Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.

  2003cited by this paper
• Effect of Peroxisome Proliferator–Activated Receptor-&agr; and -&ggr; Activators on Vascular Remodeling in Endothelin-Dependent Hypertension

  2003cited by this paper
• Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused Rats: Role of Peroxisome Proliferator–Activated Receptor-&ggr;

  2002cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone

  2002cited by this paper
• Rosiglitazone Treatment Restores Renal Dopamine Receptor Function in Obese Zucker Rats

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study.

  2002cited by this paper
• The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

  2002cited by this paper
• Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

  2002influential reference
• Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function.

  2002cited by this paper
• Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

  2002cited by this paper
• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

  2002cited by this paper
• Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.

  2001cited by this paper
• Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

  2001influential reference
• Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.

  2001cited by this paper
• Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001cited by this paper
• Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

  2001cited by this paper
• Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats.

  2001cited by this paper
• Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure

  2001cited by this paper
• Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why)

  2001cited by this paper
• Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.

  2001cited by this paper
• Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

  2001cited by this paper
• Insulin resistance and its treatment by thiazolidinediones.

  2001cited by this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE

  2001cited by this paper
• Insulin resistance and its treatment by thiazolidinediones.

  2001cited by this paper
• Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.

  2000influential reference
• Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.

  2000cited by this paper
• Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study.

  2000cited by this paper
• Dietary fat‐induced increase in blood pressure and insulin resistance in rats

  2000cited by this paper
• Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.

  2000cited by this paper
• Effects of a low‐energy diet and an insulin‐sensitizing agent on ambulatory blood pressure in overweight hypertensive patients

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

  2000cited by this paper
• Renal protective effect of troglitazone in Wistar fatty rats.

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

  2000cited by this paper
• The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

  1999cited by this paper
• Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.

  1999cited by this paper
• Altered pressure-natriuresis in obese Zucker rats.

  1999cited by this paper
• Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.

  1999cited by this paper
• Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats.

  1999cited by this paper
• Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.

  1999influential reference
• Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation.

  1999cited by this paper
• Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

  1999cited by this paper
• Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone

  1998cited by this paper
• Hepatic dysfunction associated with troglitazone.

  1998cited by this paper
• Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

  1998cited by this paper
• Direct Vasodepressor Effects of Pioglitazone in Spontaneously Hypertensive Rats

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy

  1998cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone

  1998influential reference
• Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM

  1997cited by this paper
• Characterization of renin activity in brown adipose tissue.

  1997cited by this paper
• Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats.

  1997cited by this paper

• Effects of N3SA Analogues on Cerebral and Peripheral Arteriolar Vasomotion in Spontaneously Hypertensive Rats

  2026cites this paper
• Pioglitazone in diabetic kidney disease: forgotten but not gone

  2022influential citation
• Diabetes and the Cardiovascular System

  2020cites this paper
• Thiazolidinediones Cause Cardiotoxicity via PPARγ- Independent Mechanism

  2018cites this paper
• Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan

  2017cites this paper
• A review of chemical therapies for treating diabetic hypertension

  2017cites this paper
• PREDICTION OF NOVEL THERAPEUTIC INDICATION FOR ROSIGLITAZONE USING ITS REPORTED CLINICAL SIDEEFFECTS: DRUG REPOSITIONING BY PHARMACOVIGILANCE APPROACH

  2017cites this paper
• Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.

  2017cites this paper
• Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.

  2017cites this paper
• Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor

  2016cites this paper
• Cardiovascular Risk Factors: Hypertension

  2016cites this paper
• Hypertension in type 2 diabetes: impact of glucose-lowering medications

  2016cites this paper
• Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

  2015cites this paper
• Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure

  2015cites this paper
• Peroxisome Proliferator‐activated Receptor‐γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats

  2015cites this paper
• Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

  2015cites this paper
• Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents

  2015cites this paper
• Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction

  2014cites this paper
• THE NEPHROPROTECTIVE EFFECT OF ANTIHYPERTENSIVE TREATMENT

  2014cites this paper
• A ropinirol és a rosiglitazon proarrhythmiás hatásának vizsgálata kutya kamrai szívizomsejteken

  2013cites this paper
• 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

  2013cites this paper
• Pre and postjunctional effects of rosiglitazone on the isolated rat aorta and heart

  2012cites this paper
• Pioglitazone treatment increases COX‐2‐derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function

  2012influential citation
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012cites this paper
• Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study

  2012cites this paper
• НЕФРОПАТИИ MOLECULAR MECHANISMS OF FUNCTIONING RENAL TUBULES IN DIABETES MELLITUS: DECISION ON A NEW STRATEGY OF PROPHYLACTICS AND TREATMENT OF DIABETIC NEPHROPATHY

  2012cites this paper
• Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

  2011cites this paper
• Prevention of Atherosclerosis in Overweight/Obese Patients

  2011cites this paper
• Prevention of atherosclerosis in overweight/obese patients. - In need of novel multi-targeted approaches-.

  2011cites this paper
• PPAR-γ agonism for cardiovascular and renal protection.

  2011cites this paper
• Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca.

  2011cites this paper
• ROLE OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) IN OBESITY-ASSOCIATED HYPERTENSION

  2011cites this paper
• Regulación por PPARy de la expresión vascular de COX-2 Y la producción de especies reactivas de oxigeno en hipertensión

  2011cites this paper
• Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?

  2010cites this paper
• Pioglitazone and mechanisms of CV protection.

  2010cites this paper
• Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

  2010cites this paper
• Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals

  2010cites this paper
• Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs

  2010cites this paper
• Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil.

  2010cites this paper
• Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes

  2010cites this paper
• Effects of thiazolidinediones beyond glycaemic control.

  2009cites this paper
• Thiazolidinediones and Cardiovascular Risk — A Question of Balance

  2009cites this paper
• Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes

  2009cites this paper
• Management of hypertension in patients with diabetes: the place of angiotensin‐II receptor blockers

  2009cites this paper
• Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial

  2009cites this paper
• Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes

  2008cites this paper
• Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update

  2008cites this paper
• Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity

  2008cites this paper
• Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians.

  2008cites this paper
• Thiazolidinediones for elderly patients with Type 2 diabetes: safe or not?

  2008cites this paper
• 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

  2007cites this paper
• 2013 ESH/ESC Guidelines for the management of arterial hypertension

  2007cites this paper
• Antihypertensive agents, insulin sensitivity, and new-onset diabetes

  2007cites this paper
• Hypertension in Racial and Ethnic Minorities

  2007cites this paper
• Arteriyel Hipertansiyon Tedavisi 2007 K›lavuzu Avrupa Hipertansiyon Dernei (ESH) ve Avrupa Kardiyoloji Dernei (ESC) Arteriyel Hipertansiyon Tedavisi Görev Grubu

  2007cites this paper
• Rosiglitazone and cardiovascular risk: weighing recent evidence.

  2007cites this paper
• Review: Insulin and endothelin: an interplay contributing to hypertension development?

  2007cites this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cites this paper
• Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1‐year treatment in non‐diabetic subjects with insulin resistance

  2007cites this paper
• Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).

  2007cites this paper
• Clinical trials in nephrology: success or failure

  2007cites this paper
• PPARγ agonists—Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes

  2007cites this paper
• Grupa Zadaniowa European Society of Hypertension (ESH) i European Society of Cardiology (ESC) ds. leczenia nadciśnienia tętniczego

  2007cites this paper
• Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry.

  2007cites this paper
• Combination Therapy With Telmisartan and Spironolactone Alleviates L-NAME Exacerbated Nephrosclerosis With an Increase in PPAR-γ and Decrease in TGF-β1

  2007cites this paper
• Effects of thiazolidinediones on blood pressure

  2007cites this paper
• 2007 ESH‐ESC Guidelines for the management of arterial hypertension

  2007cites this paper
• Insulin and Endothelin: An Interplay Contributing to Hypertension Development?

  2007cites this paper
• 2007 Guidelines for the management of arterial hypertension

  2007cites this paper
• 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European

  2007cites this paper
• [ESH/ESC 2007 Guidelines for the management of arterial hypertension].

  2007cites this paper
• Effects of impaired glucose metabolism on heart rate variability and blood pessure variability in essential hpertensive patients

  2006cites this paper
• Effects of impaired glucose metabolism on heart rate variability and blood pessure variability in essential hpertensive patients

  2006cites this paper
• Effects of impaired glucose metabolism on heart rate variability and blood pessure variability in essential hpertensive patients

  2006cites this paper